Immix Biopharma (IMMX) Other Non Operating Income (2021)

Immix Biopharma (IMMX) reported Other Non Operating Income of $728768.0 for Q4 2021, up 909.74% sequentially from -$90000.0 in Q2 2021.

Immix Biopharma (IMMX) Other Non Operating Income (2021) Analysis & Trends

Immix Biopharma (IMMX) has 1 years of Other Non Operating Income data on file, last reported at $728768.0 in Q4 2021.

For the quarter ending Q4 2021, Other Non Operating Income changed N/A year-over-year to $728768.0; the trailing twelve-month figure through Dec 2021 stood at -$186232.0 (changed N/A YoY), and the FY2025 full-year result was $2.1 million, up 4395.21% from the prior year.
Other Non Operating Income improved to $728768.0 in Q4 2021, from -$90000.0 in the prior quarter.
In the past five years, Other Non Operating Income ranged from a high of $728768.0 in Q4 2021 to a low of -$825000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-

Download Data